Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I clinical trial of TFC-039 for the treatment of Type 2 diabetes

Trial Profile

A Phase I clinical trial of TFC-039 for the treatment of Type 2 diabetes

Planning
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs TFC-039 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2019 According to a Sirona Biochem media release, the company is planning to meet Wanbang Biopharmaceuticals and anticipate a joint announcement on progress regarding the status of CFDA testing after the Chinese New Year.
    • 28 Aug 2018 According to a Sirona Biochem media release, this trial is anticipated to begin as early as October 2018.
    • 16 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top